Prothena Announces Appointment of Chief Regulatory Officer
(Thomson Reuters ONE) -
DUBLIN, Ireland, Dec. 15, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc
(NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the
discovery, development and commercialization of novel protein immunotherapies,
announced today the appointment of Carol D. Karp as Chief Regulatory Officer.
Ms. Karp will lead Prothena's Quality, Regulatory and Safety organizations.
This new position adds important expertise in line with Prothena's continued
growth as a late-stage clinical biotechnology company with integrated research,
development and commercial capabilities.
"Carol is a highly regarded leader who has successfully led global regulatory,
quality and safety activities across multiple therapeutic areas and all stages
of product development," said Gene Kinney, PhD, President and Chief Executive
Officer of Prothena. "She joins Prothena as we are making steady advances across
our pipeline and continue to prepare our commercial infrastructure in advance of
key clinical data. We are delighted to have someone with Carol's expertise join
our team to lead these key strategic activities."
Prior to joining Prothena, Ms. Karp was an independent regulatory consultant
with an extensive and successful track record of leading global registration
activities for innovative new products in the biotechnology and pharmaceutical
sectors. Ms. Karp previously held executive leadership positions as Senior Vice
President of Regulatory Affairs and Compliance at Esperion Therapeutics, and
Vice President and Head of Global Regulatory Affairs, Pharmacovigilance & Risk
Management at Janssen Alzheimer Immunotherapy, a Johnson & Johnson Company,
where she led global regulatory affairs, regulatory operations and CMC
regulatory for a portfolio of neurodegenerative product candidates. Prior to
Janssen, Ms. Karp was Senior Vice President, Regulatory Affairs, Quality
Assurance and Drug Safety at CV Therapeutics, which was acquired by Gilead
Sciences. Ms. Karp also held senior regulatory and scientific affairs positions
at PowderJect, VIVUS, Cygnus and Janssen Pharmaceutica.
Ms. Karp is a member of the Board of Trustees at the University of Rochester,
and an expert advisor and member of the selection and review committees for the
Stanford University School of Medicine's SPARK translational research program.
Ms. Karp earned her BA in biology from the University of Rochester.
About Prothena
Prothena Corporation plc is a global, late-stage clinical biotechnology company
seeking to fundamentally change the course of progressive diseases with its
clinical pipeline of novel therapeutic antibodies. Fueled by its deep scientific
understanding built over decades of research in protein misfolding and cell
adhesion - the root causes of many serious or currently untreatable amyloid and
inflammatory diseases - Prothena is establishing a fully integrated research,
development and commercial focus and has advanced several drug candidates into
clinical studies while pursuing discovery of additional novel therapies. Our
pipeline of antibody-based product candidates targets a number of potential
indications including AL amyloidosis (NEOD001), Parkinson's disease and other
related synucleinopathies (PRX002), inflammatory diseases, including psoriasis
and psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004). For more
information, please visit the company's website at www.prothena.com.
Contacts
Investors: Tran Nguyen, CFO
650-837-8535, IR(at)prothena.com
Media: Ellen Rose
650-922-2405, ellen.rose(at)prothena.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Prothena Corporation plc via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 15.12.2016 - 22:05 Uhr
Sprache: Deutsch
News-ID 513339
Anzahl Zeichen: 4336
contact information:
Town:
DUBLIN
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 286 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Prothena Announces Appointment of Chief Regulatory Officer"
steht unter der journalistisch-redaktionellen Verantwortung von
Prothena Corporation plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
